Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy
Aim: Few studies have investigated the course of liver stiffness after treatment with protease inhibitors. We evaluated the impact of this therapy on liver fibrosis measured by transient elastography.
Methods: This multicenter observational, cohort, prospective study included 90 patients with hepatitis C genotype 1 treated with telaprevir or boceprevir who had advanced fibrosis evidenced by liver stiffness (≥9.5 kPa). Liver stiffness was measured at baseline and 24 weeks after treatment ended, and was compared with virological responses at week 12.
Results: Liver stiffness decreased in 89% of patients who achieved su...
Source: European Journal of Gastroenterology and Hepatology - February 2, 2016 Category: Gastroenterology Tags: Original Articles: Hepatitis Source Type: research
New approaches in the treatment of hepatitis C.
Abstract
About 130-170 million people, is estimated to be infected with the hepatitis C virus (HCV). Chronic HCV infection is one of the leading causes of liver-related death and in many countries it is the primary reason for having a liver transplant. The main aim of antiviral treatment is to eradicate the virus. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin (PEG/RBV). However, in genotypes 1 and 4 the rates of viral response did not surpass 50%, reaching up to 80% in the rest. In 2011 approval was given for the first direct acting ant...
Source: World Journal of Gastroenterology : WJG - January 28, 2016 Category: Gastroenterology Authors: González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J Tags: World J Gastroenterol Source Type: research
NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment‐naïve subjects
This study evaluated HCV protease resistance profiles in the major six HCV genotypes and identified genetic barrier (GB) profiles to each available protease inhibitor across HCV strains from different locations worldwide. We obtained 15 099 HCV sequences from treatment‐naïve subjects retrieved at the Los Alamos HCV Sequence Database. The wild‐type codons of different HCV genotypes were used to analyse the smallest number of nucleotide substitution steps required for changing that codon to the closest one associated with drug resistance. The 36L and 175L RAVs were found as genetic signatures of genotypes 2‐5, while ...
Source: Journal of Viral Hepatitis - January 18, 2016 Category: Infectious Diseases Authors: L. L. Vidal, M. A. Soares, A. F. Santos Tags: Review Source Type: research
Screening of protease inhibitors resistance mutations in hepatitis c virus isolates infecting romanian patients unexposed to triple therapy.
SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.
Roum Arch Microbiol Immunol. 2015 Jan-Jun;74(1-2):7-17
Authors: Dinu S, Calistru PI, Ceauşu E, Târdeil G, Oprişan G
Abstract
Although the European recommendations include the use of new antiviral drugs for the treatment of hepatitis C, in Romania the current treatment remains interferon plus ribavirin. First generation viral protease inhibitors (i.e. boceprevir, telaprevir), which have raised the chances of obtaining viral clearance in up ...
Source: Roumanian Archives of Microbiology and Immunology - January 14, 2016 Category: Microbiology Tags: Roum Arch Microbiol Immunol Source Type: research
An Improved and Enantioselective Preparation of the
Telaprevir Bicyclic [3.3.0] Proline Intermediate and Reuse of Unwanted
Enantiomer
Organic Process Research & DevelopmentDOI: 10.1021/acs.oprd.5b00345 (Source: Organic Process Research and Development)
Source: Organic Process Research and Development - January 12, 2016 Category: Chemistry Authors: Lin-Wei Liu, Fei-Ying Wang, Fang Tian, Lin Peng and Li-Xin Wang Source Type: research
Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C
This study was carried out to evaluate factors associated with relapse after triple therapy. Materials and Methods: A prospective, multicentric study was conducted in chronic hepatitis C patients who received telaprevir-based triple therapy. We evaluated independent variables such as age, with or without cirrhosis, prior treatment response to interferon (IFN) therapy, IL28B genotype, core amino acid (aa) 70 mutation, drug adherence, white blood cell counts, hemoglobin level, and serum low-density lipoprotein (LDL) cholesterol level. The characteristics of the patients who relapsed after achieving ETR were compared with tho...
Source: Journal of Postgraduate Medicine - January 5, 2016 Category: Internal Medicine Authors: C KondoM AtsukawaA TsubotaN ShimadaH AbeY Aizawa Source Type: research
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C
Summary
The outcome of triple therapy with protease inhibitors (PI) depends on the intrinsic response to interferon. Interferon‐stimulated gene (ISG) expression differs by cell type in the liver and is a strong predictor of interferon responsiveness. Patients who respond well to interferon have low/absent ISG expression in hepatocytes but significant ISG expression in macrophages. Nonresponders (NRs) show the opposite pattern. We aimed to determine the association between cell‐type‐specific ISG staining and treatment outcome with PI‐based triple therapy. Liver biopsy tissue from consecutive patients treated with bo...
Source: Journal of Viral Hepatitis - December 29, 2015 Category: Infectious Diseases Authors: A. Duarte‐Rojo, S. E. Fischer, O. Adeyi, D. Zita, M. G. Deneke, N. Selzner, L. Chen, M. Malespin, S. J. Cotler, I. D. McGilvray, J. J. Feld Tags: Original Article Source Type: research
Volume: 26 Issue: 6
Michel G Bergeron ?MGB? ? a true success
Digging for new solutions
Invasive disease due to Haemophilus influenzae type A in children in Canada?s north: A priority for prevention.
Letter to the Editor: Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients
An unusual case of abdominal pain
Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A)<span ...
Source: Canadian Journal of Infectious Diseases and Medical Microbiology - December 23, 2015 Category: Infectious Diseases Source Type: research
The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK
Conclusion: Daclatasvir-based regimens are expected to be highly cost-effective for the majority patients with advanced disease versus relevant comparator regimens, including newer direct-acting antiviral regimens. (Source: European Journal of Gastroenterology and Hepatology)
Source: European Journal of Gastroenterology and Hepatology - December 23, 2015 Category: Gastroenterology Tags: Original Articles: Hepatitis Source Type: research
Postepy Hig Med Dosw 2015; 69:946-963 "Novel methods of hepatitis C treatment and prevention"
Despite available treatment, Hepatitis C remains one of most serious burdens to public health. Current therapy based on pegylated interferon-alpha and ribavirin has significant side effects and its effectiveness varies for different genotypes of the virus. Four novel drugs – viral protease inhibitors (telaprevir, boceprevir, simeprevir) and polymerase inhibitor – sofosbuvir have been introduced in last years for use in combination with standard-of-care treatment. For the first time interferon free therapies were approved with the use of combination of sofosbuvir+ribavirin. New therapies improve virological response rat...
Source: Postepy higieny i medycyny doswiadczalnej - December 22, 2015 Category: Research Tags: Review article Source Type: research
Hepatitis C genotype 4: The past, present, and future.
Authors: Abdel-Ghaffar TY, Sira MM, El Naghi S
Abstract
Hepatitis C virus (HCV) genotype (GT) 4 represents 12%-15% (15-18 million) of total global HCV infection. It is prevalent in Northern and Equatorial Africa and the Middle East, and is also present in some countries in Europe. GT-4 (and subtype 4a in particular) dominates the HCV epidemic in Egypt. In underdeveloped countries, risk factors associated with HCV infection may be due to unsafe medical practices or other factors such as familial transmission, mother's HCV status, or illiteracy. HCV prevention and control programs should include health educa...
Source: World Journal of Hepatology - December 19, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.
CONCLUSION: SVR12 rates were almost identical following propensity score matching.
PMID: 26668696 [PubMed] (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - December 19, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy.
Conclusions Data from this real-life study confirm the efficacy reported in clinical trials, although cirrhosis appears to play a smaller role in influencing treatment efficacy. Moreover, RVR is the only independent predictive factor of response regardless of cirrhosis. Based on RVR and for patients with cirrhosis, a shorter therapy might be considered, at least with telaprevir-based therapy.
PMID: 26672601 [PubMed - as supplied by publisher] (Source: Reviews on Recent Clinical Trials)
Source: Reviews on Recent Clinical Trials - December 17, 2015 Category: Cancer & Oncology Authors: Morisco F, Masarone M, Rosato V, Camera S, Granata R, Tartaglione MT, Coppola C, Coppola N, Megna AS, Gentile I, De Luna A, Federico A, Precone D, Claar E, Abenavoli L, Persico M Tags: Rev Recent Clin Trials Source Type: research
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study
Conclusions
In treatment-naive/-experienced HCV-1/HIV-1 patients there were significantly higher SVR rates with telaprevir-based therapy compared with pre-specified historical controls, and safety comparable to that in HCV-monoinfected patients. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - December 16, 2015 Category: Microbiology Authors: Montes, M. L., Nelson, M., Girard, P.-M., Sasadeusz, J., Horban, A., Grinsztejn, B., Zakharova, N., Rivero, A., Durant, J., Ortega-Gonzalez, E., Lathouwers, E., Janssen, K., Ouwerkerk-Mahadevan, S., Witek, J., Gonzalez-Garcia, J. Tags: Original research Source Type: research
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
Conclusion Our results suggest that the screening of rs12979860 may remain interesting for decision making in prior relapse HCV-1 Caucasian patients with compensated cirrhosis eligible for a telaprevir- or boceprevir-based therapy. (Source: PLoS One)
Source: PLoS One - December 15, 2015 Category: Biomedical Science Authors: Frédégonde About et al. Source Type: research
